Company performance
Add to research
Current Price
as of Apr 17, 2025$61.74
P/E Ratio
N/A
Market Cap
$3.9B
Description
Add to research
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.
Metrics
Add to research
Overview
- HQBoston, MA
- SectorHealth Technology
- IndustryBiotechnology
- TickerRYTM
- Price$61.74+0.65%
Trading Information
- Market cap$3.90B
- Float90.07%
- Average Daily Volume (1m)942,560
- Average Daily Volume (3m)632,598
- EPS-$4.34
Company
- Revenue$130.13M
- Rev growth (1yr)68.06%
- Net income-$260.60M
- Gross margin89.18%
- EBITDA margin-202.83%
- EBITDA-$263.94M
- EV$3.35B
- EV/Revenue25.75
- P/EN/A
- P/S28.94
- P/B177.28
- Debt/Equity1,180.76
Documents
Add to research
SEC Filings
Earnings Calls
Factset Street Account